Vitamin D Supplementation in Individuals With a Chronic Spinal Cord Injury
Key facts
- Who runs it
- Swiss Paraplegic Research, Nottwil
- Where
- Switzerland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 50 people enrolled
- Started
- 19 May 2021
- Ended
- 23 Jan 2024
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Cholecalciferol (Vitamin D3)
- Placebo
- Record updated
- 8 March 2024
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Informed Consent to the present study as documented by a signature
- Chronic (> 3 years) traumatic or non-traumatic spinal cord injury with a sub-C4-level lesion
- Wheelchair dependency during activities of daily living
- vitamin D status <75nmol/L
Who cannot take part
- Contraindications to the investigational product
- Visiting a country with increased sun exposure (below the 37th parallel north) within the last month before study enrolment or during the study
- Clinically relevant disorders,
- Pressure ulcer grade 3 or 4
- Pregnancy, breastfeeding
- Vitamin D supplementation (> 400 IU/day) within the last 12 months
- Fractures in both arms and/or both legs within the last five years
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main objective of this placebo-controlled randomized double-blinded study is to investigate the effect of vitamin D supplementation on vitamin D status (25(OH)D concentration in the blood) among individuals with a chronic spinal cord injury (SCI). Further, the effects of vitamin D supplementation on several other parameters (e.g. bone density and mood) are investigated, which could reveal positive secondary effects of supplementation that are especially relevant for clinical practice.
The 3 groups in the trial
- "Low" doseTreatment being tested
One vial with 600 µg cholecalciferol (corresponding to a total of 24'000 IU vitamin D) and one vial with placebo every month.
Treatment: Cholecalciferol (Vitamin D3) and Placebo
- "High" doseTreatment being tested
Two vials with 600 µg cholecalciferol each (corresponding to a total of 48'000 IU vitamin D) every month.
Treatment: Cholecalciferol (Vitamin D3)
- PlaceboPlacebo, for comparison
Two vials with a placebo every month.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Vitamin D Supplementation in Individuals With a Chronic Spinal Cord Injury - a Placebo-controlled Randomized Double-blinded Study
- Publications
- No discernible effect of vitamin D supplementation on secondary outcomes in chronic spinal cord injury: Findings from a randomized controlled trial.The journal of spinal cord medicine, 2025
- Vitamin D supplementation in chronic spinal cord injury (VitD-SCI): study protocol for a randomised controlled trial.BMJ open, 2021
- Record updated
- 8 March 2024